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A B S T R A C T
Rationale and objective: Cancer burden is increasing in Central and South America (CSA). We describe the
current burden of cancer in CSA.
Methods: We obtained regional and national-level cancer incidence data from 48 population-based
registries (13 countries) and nation-wide cancer mortality data from the WHO (18 countries). We
estimated world population age-standardized incidence and mortality rates per 100,000 person-years.
Results: The leading cancers diagnosed were prostate, lung, breast, cervix, colorectal, and stomach, which
were also the primary causes of cancer mortality. Countries of high/very high human development index
(HDI) in the region experienced a high burden of prostate and breast cancer while medium HDI countries
had a high burden of stomach and cervical cancers. Between countries, incidence and mortality from all
cancers combined varied by 2–3-fold. French Guyana, Brazil, Uruguay, and Argentina had the highest
incidence of all cancers while Uruguay, Cuba, Argentina, and Chile had the highest mortality. Incidence of
colorectum, prostate and thyroid cancers increased in Argentina, Brazil, Chile and Costa Rica from 1997 to
2008, while lung, stomach and cervical cancers decreased.
Conclusion: CSA carries a double-burden of cancer, with elevated rates of infection- and lifestyle-related
cancers. Encountered variation in cancer rates between countries may reﬂect differences in registration
practices, healthcare access, and public awareness. Resource-dependent interventions to prevent, early
diagnose, and treat cancer remain an urgent priority. There is an overwhelming need to improve the
quality and coverage of cancer registration to guide and evaluate future cancer control policies and
programs.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Countries in Central and South America (CSA) have undergone
signiﬁcant economic and social changes during the last few
decades [1,2]. Declines in reproductive patterns, urbanization and
increases in life expectancy are leading to major changes in the
population structure and associated increases in the burden of$ This is an Open Access article published under the CC BY NC ND 3.0 IGO license
which permits users to download and share the article for non-commercial
purposes, so long as the article is reproduced in the whole without changes, and
provided the original source is properly cited. This article shall not be used or
reproduced in association with the promotion of commercial products, services or
any entity. There should be no suggestion that IARC endorses any speciﬁc
organisation, products or services. The use of the IARC logo is not permitted. This
notice should be preserved along with the article’s original URL.
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creativecommons.org/licenses/by-nc-nd/3.0/igo/).non-communicable diseases, including cancer [1]. GLOBOCAN
estimates of 2012 indicated that annually 1 million new cancer
cases and 500,000 cancer deaths occurred in CSA; these ﬁgures are
expected to nearly double by the year 2030 (1.7 million new cases
and 1 million cancer deaths) because of ageing and population
growth. The cancer proﬁle is changing and cancers such as prostate
and breast cancer are increasingly common in CSA [3,4] probably
reﬂecting changes in reproductive and lifestyle factors related to
economic development (i.e. increasing age at ﬁrst childbirth, lower
parity, tobacco smoking, alcohol use, diets low in fruits and
vegetables, obesity, and physical inactivity) [4–10]. As a result, the
region is facing a double cancer burden with high rates of
infection-related cancers (i.e. cervix, stomach and liver) and an
increase in (Western) lifestyle related cancers (i.e. prostate, breast,
and colorectum) [2–4,11].
Epidemiologic data on the cancer burden from CSA derives
mainly from mortality data; information regarding the incidence
of cancer, though improving, remains variable in its availability.. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
emWhile the number of population-based cancer registries (PBCR) in
CSA has increased in recent years, only a small number have met
the data quality standards to be included in the last edition of
Cancer Incidence in Five Continents (CI5), covering 8% of the
population [12]. Statistics on population cancer incidence and
mortality are essential to identify disparities in cancer burden, to
develop and evaluate cancer control programs, and to guide future
research [8]. In this paper, we provide an overview of cancer
patterns in CSA, including previously unpublished incidence data.
2. Methods
The data sources and methods are described in detail in an
earlier paper in this supplement issue. In brief, we obtained
regional and national-level incidence data from 48 population-
based cancer registries in 13 countries; and national mortality data
from the World Health Organization (WHO) mortality database for
18 countries [13]. To allow data comparisons across countries, we
used standard methods to check the incidence data consistency
and quality [14]. All incidence data were converted to the latest
version of ICD-O (ICD-O-3) [15]; the data were subsequently
translated to the 10th edition of the International Classiﬁcation of
Diseases (ICD-10) [16]. Nationwide mortality data from WHO
systematically undergo data veriﬁcation, and the data are coded in
ICD-10 to avoid misclassiﬁcation of cancer mortality over time [13].
Incidence and mortality data were available from most CSA
countries except in Honduras and Guyana where neither incidence
nor mortality data were available; French Guyana and Bolivia
where only incidence data were available; and Belize, Guatemala,
Nicaragua, Panama, Paraguay, Suriname, and Venezuela where
only mortality data were available. We estimated age-standardized
incidence (ASR) and mortality (ASMR) rates per 100,000 person-
years for 30 cancer sites (Annex 1 Table A1) using the direct
method and the world standard population [17,18]. We estimated
national ASR by aggregating the data from the available cancer
registries using a weighted average of local rates. Our trend
analysis was limited to four countries with 10 or more years of data
available (Table 1). We chose to present incidence and mortality
trends only for the countries that had both incidence and mortality
data available in order to distinguish possible determinants of
observable change over time e.g. early detection, risk factor or poor
treatment, despite that the WHO mortality database makes data
available for several countries in the region. To describe incidence
data and mortality time trends, we calculated the estimated annual
percent change (EAPC) for the 4 countries that provided
permission to use individual year of diagnosis for at least 10-
years (Table 1) using the method proposed by Esteve et al. [19]. All
EAPCs were tested for equality to zero by using the corresponding
standard errors, and considered to be statistically signiﬁcant if the
p-value 0.05. We used reallocation methods to separate cervix
and corpus uteri from imprecisely coded uterine cancer deaths
[20]. We conducted all analyses in Stata version 12.1 (StataCorp)
[21].
We also present cancer rates for the United States (US) for
2003–2007 for comparison. While incidence datasets in the CSA
S24 M.S. Sierra et al. / Cancer Epidregion were obtained directly from the registries, we extracted
incidence data from CI5 Volume X [22], using data from the
Table 1
Countries and cancer registries included in the analysis of time trends.
Country Name of registries included 
Argentina Bahia Blanca 
Brazil Aracaju, Fortaleza, Goiania, Sao Paulo 
Chile Valdivia 
Costa Rica National registry 9 oldest cancer registries included in the US National Cancer
Institute’s Surveillance, Epidemiology, and End Results (SEER)
Program, which covers approximately 10% of the US population
[23]. Similar to the countries in this report, we took mortality rates
for the US from the WHO mortality database [13].
Data on human development index (HDI) for the year 2010 were
obtained from the United Nations Development Programme and
the Institut national de la statistique et des études économiques
[24,25,27].
The CSA region was sub-classiﬁed according to geographic
location (Central America, including Cuba, and South America) and
the Global Burden of Disease study [26] (Andean, Central,
Southern, Tropical, and Caribbean) (Annex 1 Table A2).
3. Results
This study incorporates data from nearly 546,000 new cancer
cases (47% males and 53% females) and more than 2 million cancer
deaths (52% males and 48% females) from CSA between 2003 and
2007. Figs. 1–4 show the rankings across all cancer sites between
CSA countries by human development (HDI) for males and females
in 2003–2007, unless otherwise speciﬁed. Prostate, female breast,
cervix, lung, colorectum, and stomach cancers accounted for 63% of
all the incident cases and 49% of all cancer deaths in CSA in both
sexes combined.
The leading male cancers diagnosed in CSA were prostate, lung,
colorectal, stomach, and non-Hodgkin lymphoma (NHL); and the
leading female cancers were breast, cervix, colorectal, stomach,
thyroid, and lung (Figs. 1 and 3). The most frequent cancer deaths
were from stomach, prostate, lung, colorectal, and liver cancer
among males and breast, cervix, stomach, lung, colorectal, and
liver cancer among females (Figs. 2 and 4).
3.1. Overall cancer burden
The incidence of all cancers combined (excluding non-
melanoma skin cancer) varied by about 2-fold between CSA
countries. Males had up to 60% higher incidence of all cancers than
females, except in Ecuador, Peru and Mexico (male-to-female
ratios, M:F = 1:1) as well as Bolivia (M:F = 0.5:1) and El Salvador (M:
F = 0.4:1). French Guyana, Brazil, and Uruguay had the highest
incidence of all cancers among males (ASR: 297.2–307.1) and
Brazil, Uruguay and Argentina had the highest incidence among
females (210.8–236.1) whereas for most CSA countries, male
incidence rates were below 229 and female rates below 200.
Mortality rates varied by 2–3-fold between countries, and the rates
in males were about 2-fold higher than in females, except in
Guatemala, Ecuador, Peru, El Salvador, and Nicaragua (M:F = 1:1).
Uruguay, Cuba, and Argentina had the highest mortality of all
cancers among males (ASMR: 137.3–181.7) and Uruguay, Cuba and
Chile had the highest mortality among females (91.8–98.2),
whereas for most CSA countries, mortality rates were below
125 among males and below 90 among females (Fig. 5). The
incidence of all cancers combined remained stable in the
4 countries evaluated (Argentina, Brazil, Chile, and Costa Rica)
iology 44S (2016) S23–S42from 1997 to 2008. Mortality declined by about 1.5% per year in
both sexes in Chile and by 2% per year in Costa Rican females.
Period % of the national population covered
1993–2007 0.8
1997–2006 8.0
1993–2008 2.2
1985–2007 100.0
Fig. 1. Cancers ranked* by age-standardized incidence rates among males in Central and South America.
Fig. 2. Cancers ranked* by age-standardized mortality rates among males in Central and South America.
M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S23–S42 S25
Fig. 3. Cancers ranked* by age-standardized incidence rates among females in Central and South America.
Fig. 4. Cancers ranked* by age-standardized mortality rates among females in Central and South America.
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idemStable mortality rates were seen in both sexes in Argentina and
Brazil and in Costa Rican males (Tables 2 and 3).
In males, time trend analysis for Argentina, Brazil, Chile, and
Costa Rica showed declines in the incidence of lung, oesophageal,
stomach cancer, and leukaemias (except in Chile) while the
incidence of prostate, colorectal, and testicular (except in
Argentina) cancers increased, at different rates for each country.
M.S. Sierra et al. / Cancer EpIn females, declines in cervical, stomach, and gallbladder cancers
were observed whereas the incidence of breast and thyroid cancers
Table 2
Estimated annual percentage change in age-standardized incidence and mortality rate
Argentina (1998–2007) Brazil (19
Incidencea Mortality Incidence
Lip, oral cavity, and pharynx (C00–14) –4.7 –1.9 –0.8 
Esophagus (C15) –2.3 –2.1 –2.1 
Stomach (C16) –0.7 –2.0 –3.9b
Colorectum (C18–20)c 2.5 0.5 2 
Liver (C22) –0.4 –1.2 1.9 
Gallbladder (C23–24) –1.1 –0.9 –1.3 
Pancreas (C25) –9.9b 0.2 –2.9 
Larynx (C32) –6.0 –2.7 –2.8 
Lung (C33–34) –5.2b –2.1 –3.8b
Melanoma of skin (C43) –0.7 0.5 0.7 
Prostate (C61) 4.8b –0.8 2.8b
Testis (C62) –5.0 0.9 3.8 
Kidney (C64) 2.7 1.3 1.4 
Bladder (C67) 2.1 –1.1 –3.3 
Brain, CNS (C70–72) 5.3 0.9 –2.3 
Thyroid (C73) –2.0 0.9 5.5 
HL (C81) 1.7 –5.0 –0.5 
NHL (C82–85,96) 2.4 –1.0 –0.6 
Leukemia (C91–95) –9.3b –1.4 –3.8 
Other and unspeciﬁed 4.8 –0.9 2.5 
All sites but C44 –0.7 –1.0 –0.1 
HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.
a Incidence rates were estimated using aggregated data from regional cancer registr
b The estimated annual percentage change is statistically different from zero (P  0.0
c Mortality data for colorectal cancer also includes the anus (C21).
Table 3
Estimated annual percentage change in age-standardized incidence and mortality rate
Argentina (1998–2007) Brazil (199
Incidencea Mortality Incidencea
Lip, oral cavity, & pharynx (C00–14) –7.5 0.1 –0.7 
Esophagus (C15) –10.6 –1.0 –0.4 
Stomach (C16) –2.8 –2.3 –2.2 
Colorectum (C18–20)b 3.6 0.02 0.9 
Liver (C22) 0.2 –2.4 0.04 
Gallbladder (C23–24) –2.8 –1.5 –2.6 
Pancreas (C25) 1.6 0.6 –2.3 
Larynx (C32) –4.3 –1.4 0.2 
Lung (C33–34) –4.6 1.9 0.1 
Melanoma of skin (C43) –6.8 2.6 –1.1 
Breast (C50) –1.8 –0.9 –0.7 
Cervix uteri (C53) –6.7c –0.4 –4.2c
Corpus uteri (C54) –2.3 –3.9 0.3 
Ovary (C56) 4.8 0.8 –4.2 
Kidney (C64) –1.2 0.9 1.2 
Bladder (C67) 2.1 –0.9 0.4 
Brain, CNS (C70–72) 5.8 1.4 –3.0 
Thyroid (C73) 17.9c –2.9 6.2c
HL (C81) 1.6 –1.9 –0.5 
NHL (C82–85,96) –0.4 –1.3 –0.1 
Leukemia (C91–95) 0.2 –0.9 –3.6 
Other and unspeciﬁed 13.6c –1.6 3.3 
All sites but C44 –0.6 –0.6 –0.4 
HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.
a Incidence rates were estimated using aggregated data from regional cancer registr
b Mortality data for colorectal cancer also includes the anus (C21).
c The estimated annual percentage change is statistically different from zero (P  0.0increased, again, at different rates for different countries
(Tables 2 and 3).
Below we brieﬂy describe incidence and mortality patterns for
several common cancer sites, including those sites with high burden
and striking regional variations; nearly all cancer sites showed
important between-country variations and sex-disparities in cancer
incidence and mortality (Annex 1 Fig. A1). The accompanying 14
iology 44S (2016) S23–S42 S27cancer site-speciﬁc papers in this supplement issue describe in detail
the geographic and temporal patterns for major cancers.
s (per 100,000), males.
97–2006) Chile (1997–2008) Costa Rica (1997–2007)
a Mortality Incidencea Mortality Incidencea Mortality
1.1 –3.1 –1.9 –0.4 1.4
0.4 –3.0 –3.8 –1.5 –0.9
–1.4 –4.2b –3.3b –4.4b –4.4b
2.5 4.1b 1.8 3.1 2.3
2 –1.8 –0.8 0.6 –1.7
0 –2.2 –2.5 –1.5 –1.1
1.4 1.5 0.1 0.3 –0.1
–0.3 –4.1 –3.8 –1.9 –2.4
–0.3 –2.0 –1.4 –1.7 –3.6
0.5 10.2b –2.1 1.5 3.7
1.6 3.2b –0.8 3.8b –0.5
2.8 4.5b –2.9 4.4 4.6
2.7 7.3b –0.8 1.1 –0.3
0.7 –1.4 0.4 –1.4 4.1
1.6 5.1 2 –1.4 –0.6
–0.04 –1.4 –0.9 4.7 8.9
–2.6 0.4 –7.6 –1.5 –6.1
0.4 –2.9 –0.3 1.5 2.8
1.2 2.9 –0.9 –3.5 –0.8
– – –3.2 –1.6 –0.1 0.2
0.7 0.4 –1.5b 0.3 –1.3
ies.
5).
s (per 100,000), females.
7–2006) Chile (1997–2008) Costa Rica (1997–2007)
Mortality Incidencea Mortality Incidencea Mortality
1.3 4.3 0.4 1.4 –1.1
0.2 –5.8 –3.8 –5.7 –8.8
–1.3 –3.4 –3.4 –3.5 –4.5
1.8 1.4 0.5 1.9 1
0.9 –0.9 –0.3 –2.2 –3.5
–1.3 –2.1 –3.2 –3.8 –4.2
1.9 –0.8 1.6 –1.8 –1.2
–0.4 0.9 –3.2 –3.5 –4.0
2.4 –1.4 1.4 0.6 –3.4
1 1.6 –2.1 1.6 –3.3
0.4 2.5 –1.0 1.7 0.2
–0.2 –6.2c –4.4 –5.1c –8.3c
1.4 –0.8 0.1 –0.1 –1.0
0.9 –4.3 –1.1 0.2 –0.9
1 3.8 –0.1 2.4 0.7
0.8 –2.6 1.8 0.7 –1.5
2.1 –0.3 3.3 –3.0 –2.6
–0.6 6.2 –1.0 8.5c –1.8
–1.2 10.7 –2.0 –0.2 –1.3
0.6 –0.5 –0.6 2.7 6
0.8 2.8 –0.02 –1.4 –0.3
– – –5.0c –2.0 –0.1 –1.8
0.6 –0.8 –1.4c –0.1 –2.0c
ies.
5).
em3.2. Variations based on sub-regions, HDI level, and country
Within sub-regions of CSA, different cancer patterns were noted;
for instance, the incidence and mortality rates from breast cancer in
South Americawere 2–5-times higher than in Central Americawhile
the incidence and mortality rates of cervical cancer were up to 3-
times higher in Central than in South America. The incidence of
colorectal cancer was the highest in some southern and tropical CSA
countries, with rates ranging between 25.2–34.2 for males and from
16.9–24.7 for females, as compared to other parts of CSA (ASR
<16.9 and ASMR around 11 or below). Lung cancer incidence and
mortality were the highest among males in southern CSA and Cuba
(ASR: 30.5–50.2 and ASMR: 18–44.5) in comparison with males in
other CSA regions (ASR <27 and ASMR <16). The incidence and
mortality from stomach cancer was higher among males in Chile and
some countries located in central CSA (ASR: 25.3–29.1 and ASMR:
17.4–24.6) and among females in the Andean region and some
central CSA countries (ASR: 12.7–15.1 and ASMR: 9.3–11.2) than
among malesand females in otherCSA regions (ASR <22.0 and ASMR
<16.0 for males; and ASR 10.3 and ASMR <9.0 for females) (Fig. 5).
Countries with high/very high HDI such as Argentina, Brazil,
French Guyana and Uruguay, had a high burden of prostate and
breast cancer and a relatively low burden of stomach and cervical
cancer, whereas in countries of medium HDI such as Bolivia, El
Salvador, Guatemala, Nicaragua, and Suriname, the burden of
stomach and cervical cancers was relatively high (Figs.1–4). Also in
high/very high HDI countries, the incidence of breast cancer was
high (ASR: 67.7–71.2) while the incidence of cervical cancer was
low (ASR: 17.1–18.2); and, in contrast, the opposite was true for
medium HDI countries like El Salvador and Bolivia (ASR <13 for
breast vs. 22–28.9 for cervix). However, in Chile (very high HDI) the
incidence of both breast and cervical cancers was relatively low
(35.4 and 13.9, respectively), and in Peru (high HDI) the incidence
of breast cancer was low (35.1) but the incidence of cervical cancer
was high (22.1) (Fig. 5).
Interesting contrasts in cancer patterns were seen also between
countries; for example, unlike other countries in CSA, Chilean
males and females had up to 12-times higher incidence and up to
30-times higher mortality rates of gallbladder cancer. Males and
females in Argentina, Brazil, Chile, and Uruguay and males in Cuba
had 5–10-times higher mortality rates of oesophageal cancer than
males and females in any other CSA country (Fig. 5). Cuban males
and females had 5–13-times higher mortality of lung, larynx and
oropharyngeal cancers than males and females in any other CSA
country, except for lung cancer among Uruguayan males, ASMR:
44.5 (Fig. 5 and Annex 1 Fig. A1).
3.3. Variations by sex
Apart from breast cancer, only two cancer types had a higher
incidence in females compared with males: thyroid (0.16:1-to-
0.24:1), and gallbladder (M:F = 0.25:1-to-0.83:1) except in French
Guyana (M:F = 2:1) where gallbladder is twice more common in
males than in females. For other cancer sites, males had higher
rates than females; for example, M:F rate ratios for lung cancer
ranged from 2:1-to-6:1 for both incidence and mortality. M:F ratios
for stomach cancer were 3:1 for incidence and mortality (Fig. 5 and
Annex 1 Fig. A1). The most drastic M:F ratio was noted for larynx,
with incidence M:F ratio ranging from 5:1-to-14:1, except in
Bolivia (M:F = 2:1), and mortality M:F ratio ranging from 4:1-to-
21:1 (Annex 1 Fig. A1).
4. Discussion
S28 M.S. Sierra et al. / Cancer EpidThis paper provides a comprehensive overview of the most
recent incidence and mortality patterns and trends of cancer inCSA. In the last 5-years available, the most common cancer
diagnoses in the region were cancers of the prostate, lung,
colorectal, stomach, and NHL among males and cancers of the
breast, cervix, colorectal, stomach, thyroid, and lung among
females. With the exclusion of NHL and the inclusion of liver
cancer, these sites were also the most important causes of cancer
deaths. Some improvements were observed such as the declining
rates of male lung cancer in Brazil and Argentina as well as the
decline in cervical and stomach cancer rates, particularly in
countries where the burden was high. On the other hand, increased
incidence rates were observed for prostate and female thyroid
cancers. Observed patterns and trends seem to reﬂect variation in
HDI, exposure to common risk factors (Table 4), detection
practices, and disparities in healthcare access [2,3,9,11,28–33].
We also observed high incidence and mortality of gallbladder
cancer in the region, particularly in Chile with some of the highest
incidence and mortality rates in the world [13,22]; although the
reasons for the high burden of gallbladder cancer is still unknown,
the high frequency of gallstones (major determinant for gallblad-
der cancer) along with poor access to gallbladder surgery may
contribute to the observed patterns [34].
Overall, incidence and mortality rates from all cancers
combined were comparatively lower in CSA than in the US, except
for male mortality in Uruguay, Cuba, and Argentina (6–40% higher)
which could reﬂect the high mortality rates from speciﬁc cancer
sites, including those sites which usually have poor survival (i.e.
lung and stomach). Although colorectal, lung, breast, cervix, and
leukaemia have good prognosis in higher income countries, in
Uruguay, Cuba, and Argentina and other CSA countries, survival
remains lower which, again, indicates inadequate and delayed
access to healthcare (diagnosis and optimum treatment) [35].
Despite the high HDI level of French Guyana, disparities in cancer
care, particularly among those living in remote areas, have been
shown in women with advanced breast cancer and invasive
cervical cancer where mortality from these diseases could be
similar to that of neighbouring countries [36,37].
The incidence and mortality rates of all cancers combined was
twice as high in males than in females, except in Bolivia and El
Salvador; the disparity in these two countries probably reﬂects the
high rates of cervical cancer among women [11]. Although the
reasons for sex disparity in cancer risk are not fully understood,
sex-speciﬁc hormones and genetic susceptibility may play some
role alongside differential exposure to risk factors [38–40].
Declines in the incidence and mortality of all cancers combined
observed in Chile and Costa Rica from 1997 to 2008 may partially
reﬂect declines in stomach and cervical cancers. Regional differ-
ences in incidence and mortality patterns of all cancers combined
reﬂect the variability of speciﬁc cancer sites (i.e. breast, cervix,
prostate, lung, stomach, colorectum, liver, etc.) and perhaps
differences across HDI levels as well as differences in the
distribution of major determinants of cancer (i.e. H. pylori infection,
smoking), detection practices, advanced stage at cancer diagnosis,
and disparities in healthcare access [2,3,11,28,30]. Interpretation of
data patterns from all cancers combined is challenging given the
wide variation in the distribution of risk factors between and
within countries that could contribute to differences in cancer risk;
moreover, under-registration of cancer patients may lead to
underestimation of incidence and/or mortality rates. For instance,
medium HDI countries such as Nicaragua, El Salvador, Suriname,
Panama, and Paraguay, and a couple of high HDI countries like
Peru, and Ecuador had some of the lowest mortality from all
cancers combined in the world [13], if these statistics are not due to
substantial under registration, they may result from the high
competing mortality burden due to other causes such as violence,
iology 44S (2016) S23–S42ischemic heart disease, road injuries, lower respiratory infections,
among others, in these countries [41].
ASR
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Fig. 5. Age-standardized incidence (light) and mortality (dark) rates per 100,000 for selected cancers in Central and South America for the period 2003–2007, unless
otherwise speciﬁedy.
yPeriod of national mortality data matched as close as possible to the incidence period.
1Incidence rates were estimated using aggregated data from regional cancer registries.
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Fig. 5. (Continued)
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Tobacco smoking and alcohol consumption remain important
public health problems in CSA [42,43], given their high prevalence in
some countries and strong causal association with several common
cancers (Table 4). The WHO has established a framework for tobacco
control and has developed aglobal strategy to reducethe harmful use
of alcohol; while all CSA countries have (partially) implemented the
framework for tobacco control, only a few countries have started to
develop and/or implement the WHO alcohol policies [44,45]. Brazil,
Panama, and Uruguay have implemented some of the most stringent
tobacco smoking policies in the region and the prevalence of
smoking has declined there in recent decades [46–48]. These policies
are a likely cause of the declining lung cancer trends in males for
some of the higher HDI countries.
Obesity trends across CSA countries revealed a remarkable
change from underweight to overweight over the last few decades
[49,50]. High intake of energy-rich foods, combined with low levels
of physical activity are suggested to cause this marked increase in
body weight [49]. Obesity has been associated with twelve cancer
sites (Table 4) and recent estimates indicate that around 15% of the
incident cancers that occurred in CSA and the Caribbean 2012 could
be attributed to obesity, assuming a causal relationship [51]. As
obesity increases in CSA it is possible that the burden of these
cancers will increase in the future, underlining the importance of
controlling this problem.
We also observed contrasting patterns in breast and cervical
cancer by HDI levels which may reﬂect changes in risk factors (Table
4) [3,9,29,31–33] as well as disparities in healthcare access
(including screening services, early detection, and treatment of
Fig. 5. (precancerous lesions) between and within countries [2,10,33,52,53].
Changes in reproductive patterns such as a reduced number ofpregnancies and later age at ﬁrst pregnancy have been associated
with an increased risk of breast cancer [10,33]. In high HDI countries
in CSA such as Argentina, Brazil and Uruguay the burden of breast
cancer is high and fertility rates with an average of 2 children per
woman (similar to that in the US); in contrast, in medium HDI
countries like Guatemala and Nicaragua and some high HDI
countries like Peru, and Ecuador, the burden of breast cancer is
low and fertility rates range between 3 to 4 children per women [54].
In addition to the growing burden of cancers related to
economic development, the burden of cancers associated with
chronic infections and poverty remains high. The main infectious
agents associated with an increased risk of cancer are shown in
Table 4. Estimates for 2008 revealed that 17% of all the incident
cancer cases occurring in South America and Mexico were due to
infections (150,000/910,000 cases), including H. pylori, HPV, HBV,
HCV, and EBV, among others [55]. However, these estimates
underscore the importance of HPV and H. pylori infections which
are highly prevalent in CSA (12.3–20.4% [56], and 50–95% [57–59],
respectively) as compared to the relatively low prevalence of HCV
(1.4–2.5% [60]) and HBV (<2% in Central and tropical CSA, and 2–4%
in the Caribbean, Andean and Southern CSA [61]).
Nearly 90% of all the cervical, vulva, vagina, anal, penile, and
oropharyngeal cancer cases combined (75,000/84,000) in CSA could
be attributed to HPV infections, with the vast majority of these cases
being cervical cancers (68,000, 91%) [62]. As of 2006, HPV
vaccination was introduced in the national immunization schedule
among women 9–20 years old in six CSA countries [2] and by mid-
2014, 18 countries in the region offered the vaccine via public
immunization programs [63]. An ongoing clinical trial conducted in
Costa Rica suggests that HPV vaccination in women is effective in
tinued)preventing oral-HPV infection which could potentially reduce the
risk of HPV-associated oropharyngeal cancer [64].
Table 4
Potential factors associated with an increased risk of cancer in Central and South America [69,73,74].
Risk Factors Cancer site
Lifestyle
Tobacco Bone marrow (myeloid leukemia), cervix, colorectum; kidney, larynx, liver, lung; nasal cavity and paranasal sinus; esophagus, oral
cavity; ovary; pancreas; pharynx, stomach, uterus, urinary bladder
Alcohol Breast (female), colorectum, larynx; liver (hepatocellular carcinoma), esophagus, oral cavity, pharynx
Obesity Corpus uteri, ovary, postmenopausal breast, gallbladder (females), esophageal adenocarcinoma, colorectum, pancreas, kidney
Adult attained height Breast, colorectum
Dieta
Red meat, processed meat Colorectum
beta-carotene supplements (high
doses)
Lung (among smokers)
Infections
Helicobacter pylori Stomach
Human papillomavirus (HPV) Cervix, vulva, vagina, anus, penis, head and neck (oral cavity, and oropharynx and tonsil)
Hepatitis C virus (HCV) Liver (hepatocellular carcinoma), NHL
Hepatitis B virus (HBV) Liver (hepatocellular carcinoma)
Epstein–Barr virus (EBV) Burkitt’s lymphoma, HL, NHL, lymphoma, nasopharynx
Human herpesvirus type 8 (HHV–8) Kaposi’s sarcoma
Human immunodeﬁciency virus
type 1 (HIV–1)
Anus; cervix; eye (conjunctiva); HL, Kaposi sarcoma, NHL
Aﬂatoxins Liver, bile duct
Schistosoma haematobium Bladder
Opisthorchis viverrini (Liver ﬂukes) Bile duct
a Several dietary and nutritional factors have been evaluated but convincing evidence for the carcinogenic or protective effects against cancer are limited [74]: i.e. foods
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that eradication of the infection may reduce the progression of early
gastric lesions [65]. Declines in the prevalence of H. pylori infection,
along with improvements in sanitation, and preservation and
storage of foods are thought to be responsible for the worldwide
decline in stomach cancer rates over the past few decades [48,66–
68]. Despitethe reported declines, mortality fromstomachcancer in
CSA remains among the highest in the world [13] perhaps due to the
high prevalence of H. pylori and unhealthy dietary habits such as a
high consumption of processed meat and salt [69,70].
HBV can be prevented via vaccination but, currently, there are
no vaccines available for HCV [65]. The introduction of the HBV
vaccine in CSA between the 1980s and 2000 seems to coincide with
declines in liver cancer; however, the extent to which HBV and HCV
contributed to the observed rates is still unknown [2,71].
Estimates for 2002 indicate that 5–28% of the global number of
liver cancer (25,200–155,000/550,000–600,000 cases) could be
attributed to aﬂatoxin exposure; however, only 2% of these
occurred in CSA (589–2980 cases). Interestingly, in Mexico, the
estimated number of aﬂatoxin-related liver cancer (hepatocellular
carcinoma) was 11-times higher than the number of HBV-related
liver cancers (152–924 cases per 100,000 in HBV-negative people
vs. 14–83 cases per 100,000 in HBV-positive people) [72], thus,
suggesting that aﬂatoxin exposure may be an important contribu-
tor in the burden of liver cancer in this country and should be
further evaluated.
4.2. Screening programs and early detection
Differences in prostate, breast, cervical, colorectal, and thyroid
cancer rates between CSA countries may partially result from cancer
screening programs (increased medical surveillance), unequal
healthcare access and treatment services, and public awareness
[2,75–92]. For example, incidence patterns of prostate cancer likely
reﬂect differences in the use of prostate speciﬁc antigen (PSA) testing
between countries [66,78,81,83,93,94]. Moreover, community-
speciﬁc projects on particular cancers could have also led to
containing beta-carotene probably protect against esophageal cancer while red meaincreased surveillance and may explain some of the strong differ-
ences between cancer sites. For example, the Barretos CancerHospital (Sao Pablo, Brazil) has established an early detection
program which offers screening for skin, breast, cervix, and prostate
using mobile units in 231 municipalities in 6 states since 2004
[76,95].
Breast cancer mortality rates in CSA have increased over the last
few decades while in high income countries mortality has declined
mainly due to screening and effective treatment [2,31,96,97]. In
CSA, most women are diagnosed at advanced stages and only 5–
10% are diagnosed in early disease stages (stage I); this proportion
varies between and within countries likely reﬂecting inequalities
in healthcare access and inadequate medical infrastructure [2,75].
In response to the high burden of breast cancer, as of 2009, most
CSA countries have developed a legislative framework for the early
detection, diagnosis, treatment and follow-up of breast cancer
[98,99] and as of 2013, most countries have national recommen-
dations for breast cancer screening, except for Ecuador, where the
guidelines are currently under development [100].
Although cytology-based cervical cancer screening has been
introducedinall CSAcountries inthe last few decades, ithas hadlittle
impact on the burden of cervical cancer due to suboptimal coverage
and follow-up coupled with disparities in screening compliance and
poor access to healthcare [33,53,56,101–106]. However, Chile, Costa
Rica, Mexico, Brazil, Colombia and Uruguay have made some
improvements in these areas in recent years leading to better control
of cervical cancer [2,53]. Cervical cancer studies to gather informa-
tion on feasibility and effectiveness of screening, and pre-cancer
treatment in limited-resource settings are also ongoing in 5 CSA
countries [107]. It is possible that improved cervical screening
activities and treatment of pre-invasive lesions as well as improve-
ments in socioeconomic conditions could reduce the burden of
cervical cancer in the future, as has already occurred in North
America and some European countries [62,66].
4.3. Healthcare access, disease management and treatment
Several CSA countries have included cancer treatment as part of
their national health insurance coverage, focusing particularly for
robably increases the risk of pancreatic and prostate cancer [69,74].those living in poverty, resulting in increased access to health
services [1,108] and probably stable or improved survival for some
idemcancer sites amenable to treatment such as cervical, breast, colon,
ovarian, and prostate in a few CSA countries where this was
introduced [35].
In spite of the improvements in healthcare systems in CSA,
including the availability of cancer treatments (radiotherapy and
chemotherapy) in the public sector [100], inequities remain in access
to optimal cancer services due to a series of factors including
availability of and accessibility to adequate medical infrastructure,
suboptimal healthcare coverage, and lack of funding and unequal
distribution of resources for particular populations [2,75]. Health
systems in most countries are fragmented or segment-structured
and provide minimum care (focusing on emergency care); hence,
there are delays in cancer diagnosis and treatment. Such delays are
usuallyassociatedwithanadvanced-disease stageatdiagnosiswhen
treatments are less effective [1,2,75,100,108]. These factors, along
with low screening rates, could probably explain the disproportion-
ate cancer mortality in CSA as compared to several high income
countries [2].
Cervical, breast and colorectal cancer are potentially curable
with early detection and treatment (including surgery, radiother-
apy and chemotherapy), while testicular cancer, lymphoma,
sarcoma and acute lymphoblastic leukaemia are also potentially
curable with adequate treatment. Unfortunately screening and/or
treatments are not readily accessible for numerous people in low
and middle income countries [108]. Hence, differences in the
adoption of modern therapies and disparities in disease manage-
ment probably contributed to some of the observed cancer
patterns in CSA as well [67,78,109–111].
4.4. Strengths and weaknesses of study
This study has several strengths and limitations. This overview
aimed to present the current patterns and trends of cancer in CSA
and included the most readily available incidence data from
13 countries (48 cancer registries), including data not published in
the latest volume of CI5 (8 countries, 22 cancer registries) [22] and
national mortality data from 18 countries. The ﬁnal population
coverage for incidence data was 10%. Although this ﬁgure is still
low, it does represent the largest compilation of cancer incidence
data in the region and the most readily accessible data source
available to date. In the absence of national incidence data (except
for Costa Rica and Uruguay), nationwide incidence rates are
represented by aggregated data from regional registries which do
not cover the entire country and may not be representative of the
cancer burden at the national level. PBCR may differ in complete-
ness and data quality which, among other factors, depend on the
maturity of the cancer registry; this could explain why some of the
rates observed in Mexico, Bolivia and El Salvador were low.
Approximately 5% of the total number of cancers diagnosed in CSA
were classiﬁed as other and unspeciﬁed. A high proportion of cases
classiﬁed as “other and unspeciﬁed” indicates poor diagnostic
precision or inability to specify the site of the primary cancer (for
cases diagnosed using tissue from a metastasis) [12].
Rates could be inﬂuenced by differences in case ascertainment
and reporting of certain cancers across countries and registries
within the region; for example, the interpretation of liver cancer
patterns depends on the accuracy of the ICD-10 coding [112]. The
quality of national mortality data rely on completeness, coverage of
the registration, and the proportion of deaths classiﬁed as “ill
deﬁned” causes; in some CSA countries mortality data may be
considered of medium or low quality [85,113–115]. Because liver
cancer is a common metastasis location, the underlying cause of
death can easily be misclassiﬁed as the primary site instead of the
metastatic site which can also bias the rate estimations [116].
M.S. Sierra et al. / Cancer EpTherefore, differences in cancer burden between countries in this
paper must be interpreted with caution, considering the largevariation in the quality of the cancer registries included and the
quality of mortality data.
Aside from the data quality evaluations performed for data
previously submitted to CI5, evaluations of data quality for most
PBCR in the region are scarce [117–119]. For instance, in Colombia, a
recent evaluation indicated that despite good levels of complete-
ness and data quality from the PBCR of Cali and Pasto, there is under-
coverage for some speciﬁc cancer sites (i.e. liver, pancreas,
gallbladder, kidney, and leukaemia) probably because some sources
of information were omitted [117,118]; there is also under-coverage
bycancer registration in the PBCRof Bucaramanga and Manizales, as
death registries were not systematically used as a source of
information [118]. While there was no selection based on quality
criteria, all datasets received for this project were passed through
the same standard consistency control and checking procedures as
used in CI5 [22], and the results produced for this study provide a
general picture of the cancer burden in the region. However, the lack
of adequate epidemiological data in CSA limit the countries'
capacity to create and evaluate optimum cancer control activities,
including prevention and screening programs [2].
Efforts to collect cancer incidence data in CSA have been
remarkable despite the limited resources allocated to most of these
registries. However, improvements in coverage and quality of
cancer registrations in CSA are urgently needed to minimize
missing or incomplete data. Given the anticipated increase in the
cancer burden in the CSA, there is still an overwhelming need for
high quality data and increased coverage to provide vital guidance
for future cancer control activities. The Global Initiative on Cancer
Registry Development (GICR), convened by International Agency
for Research on Cancer (IARC) in 2011, aims to increase global
capacity to collect high quality population-based cancer registry
data in low and middle income-countries (http://gicr.iarc.fr/). To
address the lack of high-quality cancer data in CSA, the Latin
American Regional Hub was established in 2013 to provide
increased technical and advocacy assistance.
5. Conclusion
Over the study period, the leading cancers diagnosed in CSA
were prostate, lung, female breast, cervix, colorectal, and stomach.
These cancers, were also the primary causes of cancer mortality in
the region. The marked difference in the burden of cancer in CSA
differed according to HDI level, between countries and within the
region, and also by sex. These results conﬁrm the double cancer
burden of cancer in several CSA countries with elevated rates of
both infection-related cancers and cancers associated with more
afﬂuent lifestyles.
The cancer patterns and trends across CSA countries also reveal
differences in disease ascertainment and diagnosis, death certiﬁ-
cation, and healthcare access. The disproportionately high
mortality from cancer in some countries or regions in CSA may
reﬂect deﬁciencies in prevention, early detection and/or disease
management. There are important opportunities to reduce the
cancer burden in the future through resource-dependent inter-
ventions such as the implementation and/or strengthening of
tobacco and alcohol control policies and vaccination against HPV.
Increasing public awareness of breast, cervix, colorectum, and
prostate cancer could lead to early detection and treatment and
probably better outcomes. Finally, this study demonstrates that
there is an overwhelming need to improve the quality and
coverage of population-based cancer registries to guide future
cancer control policies and programs.
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Table A1
Deﬁnition of cancer sites.
Site Codesa Description
Oropharynx C00-C14 Lip, oral cavity and pharynx
Oesophagus C15 Oesophagus
Stomach C16 Stomach
Colorectumb C18-C20 Colon and rectum
Liver C22 Liver
Gallbladder C23-C24 Gallbladder and extrahepatic biliary tract
Pancreas C25 Pancreas
Nose, sinuses C30-C31 Nasal cavity and accessory sinuses
Larynx C32 Larynx
Lung C33-C34 Lung, trachea and bronchus
Cutaneous Melanoma C43 Melanoma of skin
Mesothelioma C45 Mesothelioma
Kaposi sarcoma C46 Kaposi sarcoma
Breast C50 Breast
Cervix C53 Cervix uteri
Corpus C54 Corpus uteri
Ovary C56 Ovary
Penis C60 Penis
Prostate C61 Prostate
Testis C62 Testis
Kidney C64 Kidney
Bladder C67 Bladder
Brain, CNS C70-C72 Brain and central nervous system (CNS)
Thyroid C73 Thyroid
Hodgkin lymphoma C81 Hodgkin lymphoma
Non-Hodgkin
lymphoma
C82-85, C96 Non-Hodgkin lymphoma
Multiple myeloma C88 + C90 Multiple myeloma
Leukaemia C91-95 Acute lymphatic, chronic lymphatic, other an
myeloid, and leukaemia, cell unspeciﬁed
All cancers combined C00-C96, but
C44
All sites but non-melanoma skin cancer
Other and unspeciﬁed
cancers
a International Classiﬁcation of Diseases, 10th revision (ICD-10).
b Mortality data also includes anus (C21).
Table A2
Subregional classiﬁcation.
Geographic location
Central America Belize, Costa Rica, Cuba, El Salvador, Guate
South America Argentina, Brazil, Bolivia, Chile, Colombia, 
Global Burden of Disease Regions [23]
Andean CSA Bolivia, Ecuador, Peru
Central CSA Colombia, Costa Rica, El Salvador, Guatema
Southern CSA Argentina, Chile, Uruguay
Tropical CSA Brazil, Paraguay
Caribbean Belize, Cuba, Guyana, SurinameAcknowledgements
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Fig. A1. Age-standardized incidence (light) and mortality (dark) rates per 100,000 for selected cancers in Central and South America for the period 2003–2007, unless
otherwise speciﬁedy.
yPeriod of national mortality data matched as close as possible to the incidence period.
1Incidence rates were estimated using aggregated data from regional cancer registries.
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